Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01119066 · ClinicalTrials.gov registry record · Phase 2
HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 422
- Enrollment target
NCT01119066: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01119066 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 422 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (217% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01119066, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 422 participants
- Enrollment target
Study Summary
The purpose of this study is to find out the effects of using a system called CliniMACS to remove Tcells from blood stem cells. Removing T-cells may help stop a side effect called Graft-Versus-Host Disease (GVHD). Some studies have been done with CliniMACS, but the Food and Drug Administration (FDA) has not yet approved it.
Interventions
- DRUG Cyclophosphamide
- DRUG Melphalan
- DRUG Busulfan
- DRUG Thiotepa
- RADIATION total body irradiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 422 participants |
| Start Date | 2010-05-03 |
| Est. Completion | 2021-03-30 |
| Phase | Phase 2 |
What the finished NCT01119066 record still lists
NCT01119066 is an interventional study that assigns participants to a tested intervention. The registered 422 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (217% higher).
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT01119066 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01119066 about?
NCT01119066 is a clinical study titled "HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies". The purpose of this study is to find out the effects of using a system called CliniMACS to remove Tcells from blood stem cells. Removing T-cells may help stop a side effect called Graft-Versus-Host Disease (GVHD). Some studies have been done with CliniMACS, but the Food and Drug Administration (FDA)...
What is the current status of trial NCT01119066?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 422 participants. The study started on 2010-05-03. Estimated completion is 2021-03-30.
What interventions are being tested in trial NCT01119066?
The interventions under investigation include: Cyclophosphamide (DRUG), Melphalan (DRUG), Busulfan (DRUG), Thiotepa (DRUG), total body irradiation (RADIATION).
Who is sponsoring clinical trial NCT01119066?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01119066's enrollment target sits among peer trials
422 91st of 2000 higher than 1,910 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04763356 · 422 participants · NA
Remote Monitoring and Management of Chemotherapy Induced Peripheral Neuropathy
- NCT06837246 · 422 participants · NA
A Clinical Trial to Assess Cognitive Effects of Cognitive Nutritional Supplement in General Population
- NCT07298967 · 422 participants · NA
ORCHARDS-AIR Study
- NCT06935591 · 423 participants · NA
Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI